IGF::OT::IGF SBIR TOPIC 347 PHASE I

癌症是美国第二大常见死因，然而，早期发现往往会大大降低死亡率。在癌症的早期检测中，一种很有前景的方法是识别肿瘤生物标志物。组织中生物标记物的鉴定比循环生物标记物更有价值，因为它们伴随着空间信息，并且有可能评估细胞类型和标记物的相互作用。目前，临床最常用的方法是免疫组化法原位检测经福尔马林固定、石蜡包埋的组织切片中的生物标志物。然而，生物标志物定位的分辨率有限，限制了定量分析。免疫荧光已广泛应用于标本的自体荧光及下限检测。Luna提议开发一种等离子体金属纳米颗粒增强荧光免疫测定试剂盒，用于肿瘤生物标志物的鉴定和定量。金属纳米粒子将近红外染料荧光增强到5000倍以上，从而大大提高了载玻片测定的灵敏度和在原子摩尔范围内的LOD。Luna的试剂盒保持高度稳定，使用非常简单，不会改变当前的分析格式和程序。

Cancer is the second most common cause of death in the United States, however, the mortality rate is often greatly reduced by early detection. One promising approach in the early detection of cancer is to identify tumor biomarkers. Identification of biomarkers in tissues can have more value than circulating biomarkers as they are accompanied by spatial information, and the possibility to assess the interaction of cell types and markers. Currently, measuring biomarkers in-situ in formalin-fixed, paraffin-embedded tissue sections by immonohistochemistry is the most common method in clinic. However, the resolution of biomarker localization is limited which restricts quantitative analysis. Immunofluorescence has been widely used in autoflurenscence of specimen and the low limit. luna proposes to develop a plasmonic metal nanoparticle enhanced fluorescense immunoassay kit for tumor biomarker identification and quantificcation. The NIR dye fluorescence is enhanced by metal noanoparticles to more than 5000 fold and thus highly increase the slide assay sensitivity and LOD to the attomolar range. Luna's kit is highly stable to keep and very simple to use and does not alter the current assay format and procedures.